Citigroup
NDRM

Citigroup’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Citigroup’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-362,703
Closed -$14.1M – 7835
2017
Q3 		$14.1M Buy
362,703
+361,984
+50,345% +$13.3M 0.01% 1003
2017
Q2 		$22K Buy
+719
New +$18.6K ﹤0.01% 6243
2017
Q1 		– Sell
-814
Closed -$18K – 7566
2016
Q4 		$18K Sell
814
-2,678
-77% -$50.1K ﹤0.01% 6575
2016
Q3 		$65K Buy
3,492
+910
+35% +$15.8K ﹤0.01% 5496
2016
Q2 		$42K Sell
2,582
-1,594
-38% -$26.9K ﹤0.01% 5684
2016
Q1 		$59K Buy
4,176
+965
+30% +$13K ﹤0.01% 6024
2015
Q4 		$54K Buy
3,211
+3,206
+64,120% +$62.4K ﹤0.01% 5892
2015
Q3 		$0 Sell
5
-146
-97% -$3K ﹤0.01% 8342
2015
Q2 		$2K Sell
151
-24
-14% -$338 ﹤0.01% 7244
2015
Q1 		$2K Sell
175
-825
-83% -$10.2K ﹤0.01% 7009
2014
Q4 		$14K Buy
+1,000
New +$7.91K ﹤0.01% 6380

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Citigroup's NDRM Position: Q4 2017 in Review

Citigroup sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 362,703 shares — an estimated $14.1M sold.

Citigroup first reported a position in NDRM in Q4 2014 and held it in 11 quarters. The position peaked at $14.1M in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Citigroup reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Citigroup sold 362,703 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $14.1M.
  • Citigroup first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2014 and held it in 11 quarters.
  • Citigroup's NeuroDerm Ltd. Ordinary Shares position peaked at $14.1M in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Citigroup's 13F filing for Q4 2017, filed 12 Feb 2018.